# Study of Single Oral Doses of HOPO 14-1 Evaluating Safety, Tolerability, Pharmacokinetics

> **NCT05628961** · PHASE1 · COMPLETED · sponsor: **SRI International** · enrollment: 42 (actual)

## Conditions studied

- Toxicity;Chemical

## Interventions

- **DRUG:** HOPO 14-1

## Key facts

- **NCT ID:** NCT05628961
- **Lead sponsor:** SRI International
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-15
- **Primary completion:** 2025-08-04
- **Final completion:** 2025-08-04
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2025-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05628961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05628961, "Study of Single Oral Doses of HOPO 14-1 Evaluating Safety, Tolerability, Pharmacokinetics". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05628961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*